Personalized medicine in idiopathic pulmonary fibrosis: Facts and promises

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 5, 2015, Pages 470-478

  Spagnolo, Paolo ^a   Tzouvelekis, Argyris ^b   Maher, Toby M ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Disease behavior; Idiopathic pulmonary fibrosis; Personalized medicine; Prognosis

Indexed keywords

CASPASE; CCL18 CHEMOKINE; CXCL13 CHEMOKINE; CYTOKERATIN 18; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 ANTIBODY; KREBS VON DEN LUNGEN 6; LYSYL OXIDASE LIKE PROTEIN 2; MATRIX METALLOPROTEINASE; MUCIN 1; MUCIN 5B; PROTEIN; PROTEIN ANTIBODY; S100A12; SEMAPHORIN 7A; T LYMPHOCYTE RECEPTOR; TOLL INTERACTING PROETIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; CELL PROLIFERATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DISEASE MARKER; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; METABOLOMICS; MICROBIOME; PERSONALIZED MEDICINE; PROTEIN CLEAVAGE; REVIEW; SIGNAL TRANSDUCTION; STANDARD; T LYMPHOCYTE ACTIVATION; TELOMERE; DISEASE COURSE; GENETIC EPIGENESIS; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; PROGNOSIS;

BIOMARKERS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRECISION MEDICINE; PROGNOSIS;

EID: 84942884150     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000187     Document Type: Review

References (84)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949-1961.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis-evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
3. Spagnolo P, Wells AU, Collard HR. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discov Today 2015; 20:514-524.
4. Richeldi L, Collard HR, du Bois RM, et al. Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. Eur Respir J 2013; 42:230-238.
5. Maher TM. Beyond the diagnosis of idiopathic pulmonaryfibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med 2013; 19:460-465.
6. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012; 18:441-446.
7. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
8. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
9. Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med 2014; 21:17-19.
10. Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011; 108:10562-10567.
11. Tanjore H, Blackwell TS, Lawson WE. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302:L721-L729.
12. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014; 307:L681-L691.
13. Maitra M, Cano CA, Garcia CK. Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-beta1 secretion. Proc Natl Acad Sci USA 2012; 109:21064-21069.
14. Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013; 143:1422-1429.
15. Maitra M, Wang Y, Gerard RD, et al. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 2010; 285:22103-22113.
16. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study ofKL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165:378-381.
17. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512.
18. Wang C, Zhuang Y, Guo W, et al. Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. PloS One 2014; 9:e104919.
19. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013; 368:2192-2200.
20. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436-441.
21. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PloS One 2013; 8:e70621.
22. Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142:1584-1588.
23. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309:2232-2239.
24. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317-1326.
25. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104:7552-7557.
26. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:729-737.
27. Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2:557-565.
28. Cha SI, Ryerson CJ, Lee JS, et al. Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir Res 2012; 13:105.
29. Dobashi N, Fujita J, Murota M, et al. Elevation of anticytokeratin 18 antibody and circulating cytokeratin 18: anticytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000; 178:171-179.
30. Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1680-1684.
31. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299:L3-7.
32. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188:1442-1450.
33. O'Dwyer DN, Armstrong ME, Kooblall M, Donnelly SC. Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opin Ther Targets 2015; 19:507-514.
34. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1:309-317.
35. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:717-723.
36. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
37. Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187:768-775.
38. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5:205ra136.
39. Kotsianidis I, Nakou E, Bouchliou I, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:1121-1130.
40. Radstake TR, van Bon L, Broen J, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PloS One 2009; 4:e5981.
41. Gan Y, Reilkoff R, Peng X, et al. Role of semaphorin 7a signaling in transforming growth factor beta1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63:2484-2494.
42. Czopik AK, Bynoe MS, Palm N, et al. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006; 24:591-600.
43. Reilkoff RA, Peng H, Murray LA, et al. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187:180-188.
44. Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:1698-1702.
45. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180:167-175.
46. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014; 2:548-556.
47. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:906-913.
48. Richards TJ, Park C, Chen Y, et al. Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302:L746-754.
49. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5:e93.
50. Jenkins RG, Simpson JK, Saini G, et al. Relating longitudinal change in collagen degradation biomarkers to outcome in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015. [Epub ahead of print]
51. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43:1430-1438.
52. Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 2012; 20:1251-1260.
53. Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45:287-294.
54. Huleihel L, Ben-Yehudah A, Milosevic J, et al. Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2014; 306:L534-L542.
55. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182:220-229.
56. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207:1589-1597.
57. Milosevic J, Pandit K, Magister M, et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 47:879-887.
58. Oak SR, Murray L, Herath A, et al. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PloS One 2011; 6:e21253.
59. Kottmann RM, Kulkarni AA, Smolnycki KA, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am J Respir Crit Care Med 2012; 186:740-751.
60. Oldham JM, Kumar D, Lee C, et al. Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2015. [Epub ahead of print]
61. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11:164-168.
62. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50:3-13.
63. Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 2014; 108:1031-1039.
64. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187:567-572.
65. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med 2014; 189:1161-1172.
66. Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
67. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010; 11:373-384.
68. Shah JA, Vary JC, Chau TT, et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J Immunol 2012; 189:1737-1746.
69. Atamas SP, Luzina IG, Choi J, et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003; 29:743-749.
70. Luzina IG, Tsymbalyuk N, Choi J, et al. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006; 206:221-228.
71. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006; 176:5735-5739.
72. Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol 2013; 191:2089-2095.
73. Ley RE, Lozupone CA, Hamady M, et al. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 2008; 6:776-788.
74. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 2006; 3:383-388.
75. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16:1009-1017.
76. Chen LJ, Li WD, Li SF, et al. Bleomycin induces upregulation of lysyl oxidase in cultured human fetal lung fibroblasts. Acta Pharmacol Sin 2010; 31:554-559.
77. [No authors listed]. At the frontiers of lung fibrosis therapy. Nat Biotechnol 2013; 31:781-783.
78. Ovet H, Oztay F. The copper chelator tetrathiomolybdate regressed bleomy-cin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions. Biol Trace Elem Res 2014; 162:189-199.
79. Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PloS One 2012; 7:e33770.
80. Yang IV, Pedersen BS, Rabinovich E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:1263-1272.
81. Montgomery RL, Yu G, Latimer PA, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 2014; 6:1347-1356.
82. Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 2014; 124:1622-1635.
83. Pathak RR, Dave V. Integrating omics technologies to study pulmonary physiology and pathology at the systems level. Cell Physiol Biochem 2014; 33:1239-1260.
84. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir J 2013; 22:148-152.